JNJ,PFE -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com9 hours ago

    Crowning Achievement: Six Dividend Kings With 50+ Years of Rising Dividends

    The "Dividend Kings" are the pinnacle of dividend stock royalty. A long dividend history is important because it proves that a company has been able to maintain its competitive advantage over the long run. This article has detailed analysis on our six favorite Dividend Kings.

  • This one factor has determined which stocks rise or fall on trade-war fears
    MarketWatch13 hours ago

    This one factor has determined which stocks rise or fall on trade-war fears

    In a volatile year for the U.S. equity market, one factor has emerged as pivotal in determining whether a stock is likely to rise amid growing concerns over trade policy: how much the U.S. company focuses on the U.S.

  • 3 Big Stock Charts for Thursday: JPMorgan Chase, Pfizer and Disney
    InvestorPlace14 hours ago

    3 Big Stock Charts for Thursday: JPMorgan Chase, Pfizer and Disney

    After moving dangerously close to the tipping point on Tuesday, the market got something of a reprieve with Wednesday’s action. FANG stocks Facebook (NASDAQ:FB) and Netflix (NASDAQ:NFLX) both moved to record highs yesterday, pulling the rest of the market up with them.

  • Investors Are Undervaluing Pfizer Inc (NYSE:PFE) By 43.43%
    Simply Wall St.14 hours ago

    Investors Are Undervaluing Pfizer Inc (NYSE:PFE) By 43.43%

    In this article I am going to calculate the intrinsic value of Pfizer Inc (NYSE:PFE) by taking the expected future cash flows and discounting them to their present value. ThisRead More...

  • Johnson & Johnson Releases Positive Study Data for Oncology Drug
    Market Realist15 hours ago

    Johnson & Johnson Releases Positive Study Data for Oncology Drug

    On June 3, Johnson & Johnson’s (JNJ) pharma subsidiary, Jannsen, released data from a Phase 2 study of erdafitinib for the treatment of patients with metastatic or unresectable urothelial carcinoma (or mUC). Johnson & Johnson presented the study results at the 2018 ASCO (American Society of Clinical Oncology) Annual Meeting, along with results for some of its other oncology drug trials, as shown in the diagram below. Jannsen’s erdafitinib, a once-daily oral pan-FGFR (fibroblast growth factor receptor) inhibitor, was designated a breakthrough therapy by the FDA in March.

  • Johnson & Johnson Receives Offer to Divest Sterilization Business
    Market Realist16 hours ago

    Johnson & Johnson Receives Offer to Divest Sterilization Business

    On June 6, Johnson & Johnson (JNJ) announced it had received a $2.8 billion offer from Fortive (FTV) to sell its ASP (Advanced Sterilization Products) business, part of its subsidiary, Ethicon. Ethicon’s ASP business, a market leader in infection prevention solutions, generated sales of $775 million in fiscal 2017. Johnson & Johnson has 120 days to decide on the offer.

  • Johnson & Johnson Accepts Sale of Its LifeScan Business
    Market Realist18 hours ago

    Johnson & Johnson Accepts Sale of Its LifeScan Business

    On June 12, Johnson & Johnson (JNJ) announced it had accepted a $2.1 billion offer for the sale of its LifeScan business, which manufactures blood glucose monitoring devices and OneTouch products, from private equity company Platinum Equity. On June 12, JNJ stock fell ~0.42% following the deal announcement.

  • How Long Should You Own a Stock?
    Zacksyesterday

    How Long Should You Own a Stock?

    These 4 criteria can guide investors through the investing maze.

  • Should You Buy Pfizer Inc (NYSE:PFE) At This PE Ratio?
    Simply Wall St.yesterday

    Should You Buy Pfizer Inc (NYSE:PFE) At This PE Ratio?

    Pfizer Inc (NYSE:PFE) is trading with a trailing P/E of 9.9x, which is lower than the industry average of 24x. Although some investors may jump to the conclusion that thisRead More...

  • How Johnson & Johnson’s Valuation Compares
    Market Realistyesterday

    How Johnson & Johnson’s Valuation Compares

    Johnson & Johnson (JNJ), one of the world’s largest healthcare companies, has a diversified business spanning its consumer, medical device, and pharmaceutical segments. The company reported sales of $20 billion in Q1 2018 and adjusted EPS of $2.06. Let’s look at Johnson & Johnson’s valuation metrics.

  • A Look at Johnson & Johnson’s Stock Performance
    Market Realistyesterday

    A Look at Johnson & Johnson’s Stock Performance

    Johnson & Johnson (JNJ) closed June 18 at $121.30 per share. The stock reached a 52-week low of $118.60 on May 29 as the company scrapped a Phase 1b/2 trial for its drug, Darzalex, for the treatment of advanced or metastatic non-small cell lung cancer patients, in combination with Roche’s (RHHBY) Tecentriq. Since then, the stock has risen ~1.6%.

  • What Analysts Recommend for Johnson & Johnson Stock
    Market Realist2 days ago

    What Analysts Recommend for Johnson & Johnson Stock

    Johnson & Johnson (JNJ) is one of the biggest healthcare players in the world. However, it has been impacted by growing competition and pricing pressure in the industry in recent years and has revised its strategy. The company has witnessed recuperating sales in its medical devices business along with improving dynamics in its consumer business, which has encountered some litigation recently. The company’s pharmaceuticals business has performed steadily, with key trial data being announced. Let’s look at analysts’ recommendations for JNJ stock.

  • Amgen Gets EU Nod to Add Survival Data on Blincyto's Label
    Zacks2 days ago

    Amgen Gets EU Nod to Add Survival Data on Blincyto's Label

    Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.

  • A Look at Allergan’s Valuation as of June 19
    Market Realist2 days ago

    A Look at Allergan’s Valuation as of June 19

    Allergan (AGN), a leading specialty pharmaceutical company, is focused on developing, manufacturing, and commercializing pharmaceutical and biologic products.

  • Forbes2 days ago

    There Go Those Drug Companies Inventing New Diseases Again

    Another quote used by Walsh, this one from Cindy Pearson of the National Women’s Health Network, claims that “Osteopenia is disease-mongering plain and simple.” Osteopenia is a term used to describe bone-thinning and is considered to be the mid-point between healthy bone and osteoporosis. Is osteopenia (bone-thinning) a disease?

  • Sarepta's Stock Soars on Encouraging Gene Therapy Results
    Zacks2 days ago

    Sarepta's Stock Soars on Encouraging Gene Therapy Results

    Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.

  • Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks
    Motley Fool2 days ago

    Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks

    J&J's dividend is good. But these are even better.

  • Here’s how much Houston public companies spent on litigation in 2017
    American City Business Journals2 days ago

    Here’s how much Houston public companies spent on litigation in 2017

    Meanwhile, the nation’s largest banks are preparing for a timeout from the courtroom following years of being pummeled by shareholder and investor lawsuits in the wake of the Great Recession.

  • What’s the Latest on Teva’s Fremanezumab?
    Market Realist2 days ago

    What’s the Latest on Teva’s Fremanezumab?

    Teva’s (TEVA) much-awaited migraine drug, Fremanezumab, is in late-stage trials for the treatment of cluster headaches. The company provided an update regarding its Enforce Phase III clinical development program for the treatment of cluster headaches on June 15.

  • TheStreet.com2 days ago

    The Charts and Indicators on Johnson & Johnson Are Still Mostly Bearish

    is another company that Jim Cramer put in his new GLOOM index last night on his Mad Money show on CNBC. In this updated daily bar chart of JNJ, below, we have more bearish signals than bullish ones. JNJ broke down below the rising 50-day moving average line in late January and the slope of the line quickly turned negative.

  • Bloomberg2 days ago

    Opioid Ruling Could Send  Purdue, Drugmakers to Court

    Purdue Pharma LP, Johnson & Johnson and other opioid makers faced one of the first extensive review of their legal defenses to state claims that they violated consumer-protection laws and created a public nuisance with the sale of the pain killers. New York state court Judge Jerry Garguilo on Monday rejected the pharma companies’ requests for the lawsuits be thrown out on a myriad of grounds, concluding lawyers for eight counties could move forward with their claims. While the ruling is based solely on New York law, it could provide a roadmap for other judges around the U.S. weighing whether states and local governments can proceed with claims that Purdue and other opioid makers understated the risks of prescription opioids and overstated their benefits.

  • Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx
    Zacks3 days ago

    Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx

    The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.

  • Forbes3 days ago

    A Gene Therapy Appears To Replace Missing Protein In Muscular Dystrophy Patients

    An experimental gene therapy appeared to dramatically increase the production of a muscle-making protein in three young boys with Duchenne muscular dystrophy, a deadly and irreversible disease, according to results being presented by the drugmaker Sarepta Therapeutics at an investor event this morning. “We think this has huge implications for the treatment of this disease,” says Jerry R. Mendell, the principal investigator in the Center for Gene Therapy at the Research Institute of Nationwide Children’s Hospital, who is leading the study for Sarepta. “Being in this field doing clinical research for many years, I learned to be cautious,” says Ron Crystal, chairman of genetic medicine at Weill Cornell Medicine.

  • Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
    PR Newswire3 days ago

    Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

    NEW BRUNSWICK, N.J., June 19, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 17, to review second-quarter results.  Alex Gorsky, Chairman and Chief Executive Officer and Joseph J. Wolk, Executive Vice President, Chief Financial Officer will host the call. The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.

  • Business Wire3 days ago

    Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With Analysts

    Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 31, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.